23andMe Wants FDA Approval for Personal DNA Testing. What Can It Reveal?
By Bonnie Rochman,
TIME Healthland
| 08. 02. 2012
Earlier this week, the personal gene-testing company 23andMe announced that
it’s seeking the blessing of the Food and Drug Administration (FDA) for
its DNA tests that allow people to peer into their genetic makeup.
If the FDA grants approval, it would be a major step forward for the
growing industry springing up around genetic testing. Every day, it
seems, scientists are reporting new gene-based discoveries that allow
them to better pinpoint the causes of disease. As technology becomes
increasingly sophisticated, single-gene tests are being joined by the
sort of genotyping technology used by 23andMe, which scans about 1
million points on the genome that are known to vary among humans. An
even more complex technique, genomic sequencing, looks at about 3
billion points that cover a person’s entire genetic code. 23andMe — the
name is a reference to the 23 pairs of chromosomes that comprise a
person’s genome — intends to eventually offer sequencing, but the cost
starts at around $4,000, which is considerably more expensive than the
$299 the company charges for its testing.
Not only is sequencing more...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
